Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Clopidogrel
Drug: Dabigatran high dose
Drug: Dabigatran low dose

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 44

Registration Number: NCT02171598

Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate
Drug: Diclofenac

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02171507

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1744 CL
Drug: Placebo

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 47

Registration Number: NCT02171806

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)

Conditions: Idiopathic Pulmonary Fibrosis

First Posted Date: 2014-06-24

Last Posted Date: 2017-05-08

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02171156

Locations: 🇺🇸
1199.177.1003 Boehringer Ingelheim Investigational Site, Winter Park, Florida, United States
🇺🇸
1199.177.1022 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
🇺🇸
1199.177.1067 Boehringer Ingelheim Investigational Site, Houston, Texas, United States

and more 4 locations

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 38

Registration Number: NCT02171637

A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1744 CL
Drug: Placebo

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 122

Registration Number: NCT02171780

Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Tiotropium bromide medium
Drug: Tiotropium bromide high
Drug: Tiotropium bromide low
Drug: Placebo

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 113

Registration Number: NCT02172534

Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992

First Posted Date: 2014-06-24

Last Posted Date: 2015-01-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 43

Registration Number: NCT02171663

Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo inhalation powder capsules
Drug: Tiotropium inhalation powder capsules

First Posted Date: 2014-06-24

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 81

Registration Number: NCT02172391

Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation

Phase 4

Terminated

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium Inhalation Capsule
Drug: Placebo Lactose Capsule

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT02172508

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy